Grifols, S.A., CSL and Takeda Pharmaceutical Company Limited is Expected to Dominate the U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market in 2021

U.S. Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market is expected to grow with the CAGR of 9.0% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-alpha-1-antitrypsin-deficiency-aatd-augmentation-therapy-market

U.S. alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in U.S. alpha-1 antitrypsin deficiency (AATD) augmentation therapy market are introducing strong range of drug products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance:

  • In November 2017, Grifols S.A. received approval from the U.S. Food and Drug Administration (FDA) for a new genetic test to detect alpha-1 antitrypsin deficiency. The authorization marks an important milestone in the industry as it is the first time the FDA has approved a biological molecular test that uses the patient's DNA for the diagnostic. This has helped the company to increase its revenue through this production.   

Grifols, S.A. is the dominating player in U.S. Alpha-1 antitrypsin deficiency (AATD) augmentation therapy market. The other key players existing in the market are CSL, Kamada Pharmaceuticals., Takeda Pharmaceutical Company Limited., and LFB BIOMEDICAMENTS. The Pipeline companies which are dealing in market includes Arrowhead Pharmaceuticals, Inc., Mereo BioPharma Group plc, Inhibrx, Inc., Centessa Pharmaceuticals (Z Factor)., Intellia Therapeutics, Inc., Apic Bio, Krystal Biotech, Beam Therapeutics, LOGICBIO THERAPEUTICS, INC., and among others.

Grifols, S.A.

Grifols, S.A. founded in the year 1909, headquartered in Barcelona, Spain. The company focuses on producing plasma-derived medicines and transfusion medicine. The company has four major business segments which includes bioscience, diagnostic, hospital and bio supplies where bioscience is market focused segment. The company has several product categories which are bioscience, diagnostic, hospital and bio supplies in which bioscience is the market focused category.

For instance

  • In September 2017, Grifols S.A. received approval from the U.S. Food and Drug Administration (FDA) for a liquid formulation of its alpha-1 antitrypsin (Prolastin-C Liquid) as a replacement therapy to treat alpha-1 antitrypsin deficiency (AATD). This has helped the company to increase its revenue through this production.

The company has presence across North America, South America, Europe, Middle East and Africa and Asia-Pacific. The subsidiaries of company includes, Biomat, S.A. (Spain), Biotest (Germany), Biomat USA Inc. (U.S.), Alkahest, Inc. (U.S.), GigaGen, Inc. (U.S.) among others.

CSL

CSL Headquarters is in Pennsylvania, U.S. founded in 2000. The company focuses on offering wide range of quality plasma derived recombinant therapies and innovating life-saving medicines for rare diseases. The company has several product categories including immunology, haematology, respiratory, albumin in which respiratory is the market focused category.

For instance,

  • In April 2019, CSL received the US Food and Drug Administration (FDA) has approved 4- and 5-gram vial sizes for ZEMAIRA  [Alpha1-Proteinase Inhibitor (Human)], its therapy for treating Alpha 1 Antitrypsin Deficiency (Alpha 1).  This approval is significant for the Alpha 1 community as ZEMAIRA was previously available only in a 1-gram vial. This has helped the company to increase its revenue with this production.   

The company has wide presence across North America, Europe and Asia-Pacific.

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited headquarter in Tokyo, Japan founded in 1781. The company focuses on discovering and delivering life transforming treatments. The company is operating with various business segments includes oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines in which plasma-derived therapies is focused segment. The company has several product categories which are oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines in which plasma-derived therapies is the market focused category.

For instance,

  • In October 2020, Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc. to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). This has helped the company to increase its global presence through this collaboration.

The company has presence across Asia-Pacific, Europe, South America and North America. The company has various subsidiaries including Takeda Canada Inc., Takeda Pharmaceuticals U.S.A., Inc., Takeda Austria, Takeda Pharmaceuticals Australia Pty. Ltd., and Takeda Belgium NV among others.